Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer

KUNIHIKO KOBAYASHI, KYOICHI KAIRA and HIROSHI KAGAMU
Anticancer Research September 2020, 40 (9) 5309-5311; DOI: https://doi.org/10.21873/anticanres.14537
KUNIHIKO KOBAYASHI
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KYOICHI KAIRA
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kkaira1970@yahoo.co.jp
HIROSHI KAGAMU
Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Experimental studies have shown that celecoxib is related to the downregulation of Tregs and an increase in the therapeutic efficacy of PD-1 inhibitors; however, such effect has not been shown in human cancers. Our report confirmed the synergistic effect of celecoxib with a PD-1 inhibitor. Case Report: A 57-year-old male with advanced pulmonary adenocarcinoma was treated with nivolumab monotherapy as 5th line sequential treatment. Although the patient experienced tumor remission, regrowth of the primary tumor was observed and he complained of lumbar pain. Therefore, celecoxib (400 mg/day) was initiated without cessation of nivolumab. Chest radiography revealed a marked shrinkage of the primary site, with a decreasing trend of carcinoma embryonic antigen. Conclusion: This is the report of a case of recovery of sensitivity to nivolumab by additional treatment with celecoxib.

  • Celecoxib
  • COX2
  • immune checkpoint inhibitor
  • PD-1
  • lung cancer

Immune checkpoint inhibitors (ICIs), such as anti-programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) antibodies, have yielded limited efficacy in patients with advanced non-small cell lung cancer (NSCLC). However, some long-term survivors after ICI treatment have been observed. To improve the efficacy of ICIs, the development of additional treatments is necessary.

Celecoxib, 4-[5-(4-methylphenyl)-3-trifluoromethyl1H-pyrazol-1-yl] benzenesulfonamide, is a specific inhibitor of cycloxygenase-2 (COX2) that diminishes inflammation and pain, and is described to be associated with downregulation of regulatory T-cells (T-regs) (1). Reportedly, celecoxib exhibits antitumor activity in various human cancers; moreover, combination therapy of celecoxib and a PD-1 inhibitor increased the efficacy of the PD-1 inhibitor in an experimental model, suggesting that celecoxib treatment can result in the recovery of a negative tumor immune environment (1). Recently, we experienced a case demonstrating the recovery of sensitivity to nivolumab due to celecoxib, in a patient with advanced NSCLC.

Case Report

A 57-year-old male with a history of smoking who harbored epidermal growth factor receptor mutation deletion 19 (cT2aN2M1) was diagnosed with pulmonary adenocarcinoma. In October 2015, gamma-knife therapy was performed owing to cerebral metastases. Subsequently, the patient was administered afatinib. As tumor recurrence with T790M was found, osimertinib was initiated in December 2016. Six months after its initiation, progressive disease was observed and cisplatin plus pemetrexed was administered. He also received erlotinib plus bevacizumab. In September 2017, nivolumab was administered for recurrent disease. Although the patient experienced tumor remission, regrowth of the primary tumor was observed in December 2019 (Figure 1) and he complained of lumbar pain. Therefore, celecoxib (400 mg/day) was initiated without cessation of nivolumab. Despite serological and bacterial investigation, there was no evidence of any disease aside from its regrowth. In January 2020, chest radiography revealed a marked shrinkage of the primary site, with a decreasing trend in the levels of carcinoma embryonic antigen (CEA) (Figure 1). The patient continues to receive nivolumab and celecoxib without any recurrence.

Discussion

To our knowledge, this is the first report of a case of recovery of sensitivity to nivolumab by additional treatment with celecoxib. The efficacy of ICIs has been reported to improve after radiation therapy, however; it remains unclear whether celecoxib could increase the efficacy of anti-PD-1 antibody.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Chest radiography before and after oral celecoxib during nivolumab administration (A, B and C) and transitive graph of CEA (ng/ml) (D). Chest radiography shows almost remission of primary tumor in the left upper lung field (A) (white arrow) during nivolumab administration, but it reveals regrowth of primary site (B) (white arrow). After celecoxib administration, chest radiography reveals obvious shrinkage of primary site (C) (white arrow). Celecoxib (400 mg/day) was initiated in December 2019.

Botti et al. have reported that COX-2 expression significantly correlates with PD-L1 expression in melanoma cells, and the COX2 inhibition by celecoxib downregulates PD-L1 expression in vitro (2).

In lung cancer, PD-L1 expression correlated with that of COX and the majority of lung cancer cells expressing PD-L1 also co-expressed COX2 (3). However, inhibition of COX2 did not affect PD-L1 expression in lung cancer cell lines (3). Likewise, the inhibition of COX2 has been described to reduce the recruitment of myeloid-derived suppressor cells (MDSCs) to the tumor sites and decrease T-regs (1, 4, 5). MDSCs have receptors for prostaglandin E2 (PGE2) and COX inhibitor decreases the production of PGE2 (6). In our case, celecoxib treatment could reestablish sensitivity to nivolumab. The additional administration of celecoxib seemed to act synergistically to ICIs. According to previous studies, any additional therapy to ICIs is expected to improve the efficacy of ICIs; thus, celecoxib is a promising drug to strengthen the immunological effects of PD-1 inhibitors. However, many cases of delayed pseudoprogression have been reported in the literature, especially in melanoma patients. Although we carefully considered whether our patient experienced delayed pseudoprogression, there was no potential of pseudoprogression related to nivolumab treatment because of obvious change in the levels of CEA as tumor marker before and after the administration of celecoxib. Moreover, it remains unclear what kind of patients can obtain the clinical benefit of anti-PD-1 antibody by the administration of celecoxib. Further study is warranted to elucidate the clinical significance of additional treatment of celecoxib to anti-PD-1 antibody for patients with various human cancers. Physicians should be alert to the potential usefulness of celecoxib in addition to PD-1 inhibitors.

Footnotes

  • Authors' Contributions

    Conception and design: Kunihiko Kobayashi. Collection and assembly of data: Kyoichi Kaira. Data analysis and interpretation: Kyoichi Kaira, Kunihiko Kobayashi. Manuscript writing: Kyoichi Kaira. Final approval of the manuscript: All Authors. Accountable for all aspects of the work: All Authors.

  • Conflicts of Interest

    K Kaira and HK have received research grants and a speaker honorarium from Ono Pharmaceutical Company and Bristol-Myers Company. All remaining Authors have declared no conflicts of interest.

  • Received June 10, 2020.
  • Revision received July 22, 2020.
  • Accepted July 23, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Li Y,
    2. Fang M,
    3. Zhang J,
    4. Wang J,
    5. Song Y,
    6. Shi J,
    7. Li W,
    8. Wu G,
    9. Ren J,
    10. Wang Z,
    11. Zou W,
    12. Wang L
    : Hyfrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology 5: e1074374, 2015. PMID: 27057439. DOI: 10.1080/2162402X.2015.1074374
    OpenUrl
  2. ↵
    1. Botti G,
    2. Fratangelo F,
    3. Cerrone M,
    4. Liguori G,
    5. Cantile M,
    6. Anniciello AM,
    7. Scala S,
    8. D'Alterio C,
    9. Trimarco C,
    10. Ianaro A,
    11. Cirino G,
    12. Caracò C,
    13. Colombino M,
    14. Palmieri G,
    15. Pepe S,
    16. Ascierto PA,
    17. Sabbatino F,
    18. Scognamiglio G
    : COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. J Transl Med 15: 46, 2017. PMID: 28231855. DOI: 10.1186/s12967-017-1150-7
    OpenUrlCrossRef
  3. ↵
    1. Shimizu K,
    2. Okita R,
    3. Saisho S,
    4. Maeda A,
    5. Nojima Y,
    6. Nakata M
    : Impact of COX2 inhibitor for regulation of PD-L1 expression in non-small cell lung cancer. Anticancer Res 38: 4637-4644, 2018. PMID: 30061230. DOI: 10.21873/anticanres.12768
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Obermajer N,
    2. Muthuswamy R,
    3. Odunsi K,
    4. Edwards RP,
    5. Kalinski P
    : PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71: 7463-7470, 2011. PMID: 22025564. DOI: 10.1158/0008-5472.CAN-11-2449
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Sharma S,
    2. Yang SC,
    3. Zhu L,
    4. Reckamp K,
    5. Gardner B,
    6. Baratelli F,
    7. Huang M,
    8. Batra RK,
    9. Dubinett SM
    : Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4C CD25C T regulatory cell activities in lung cancer. Cancer Res 65: 5211-5220, 2005. PMID: 15958566. DOI: 10.1158/0008-5472.CAN-05-0141
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Sinha P,
    2. Clements VK,
    3. Fulton AM,
    4. Ostrand-Rosenberg S
    : Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67: 4507-4513, 2001. PMID: 17483367. DOI: 10.1158/0008-5472.CAN-06-4174
    OpenUrl
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (9)
Anticancer Research
Vol. 40, Issue 9
September 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer
KUNIHIKO KOBAYASHI, KYOICHI KAIRA, HIROSHI KAGAMU
Anticancer Research Sep 2020, 40 (9) 5309-5311; DOI: 10.21873/anticanres.14537

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer
KUNIHIKO KOBAYASHI, KYOICHI KAIRA, HIROSHI KAGAMU
Anticancer Research Sep 2020, 40 (9) 5309-5311; DOI: 10.21873/anticanres.14537
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
Show more Clinical Studies

Similar Articles

Keywords

  • celecoxib
  • COX2
  • immune checkpoint inhibitor
  • PD-1
  • lung cancer
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire